Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

Post-print evidence is mixed rather than decisively bullish: adjusted EPS modestly beat one reported consensus measure, revenue missed, and Q3 GAAP results absorbed the sale charge. FHN closed at $22.86 on October 15, up about 0.8% from October 14, but the packet's October 19 adjusted close was $22.73, so the initial gain did not clearly hold. [Historical prices](https://stockanalysis.com/stocks/fhn/history/) Analyst revisions through October 16 were split, with one target increase and multiple cuts; no verified later estimate-revision series is available. [Morgan Stanley](https://www.tipranks.com/news/the-fly/first-horizon-price-target-raised-to-31-from-30-at-morgan-stanley-thefly-news) [Raymond James](https://www.tipranks.com/news/the-fly/first-horizon-price-target-lowered-to-27-from-28-at-raymond-james-thefly-news)

Mixed post-earnings tone: adjusted EPS of $0.85 narrowly exceeded the roughly $0.84 consensus cited by Zacks, while GAAP EPS was $0.76 and analysts cut targets. [Zacks earnings comparison](https://finance.yahoo.com/markets/stocks/articles/wafd-wafd-q4-earnings-revenues-004001486.html) WAFD fell from $29.45 before the release to $28.42 on October 19, about 3.5%; the price move alone does not establish its cause. [Historical prices](https://stockanalysis.com/stocks/wafd/history/) Social, options, short-interest and employee-sentiment measures were not supplied; zero values above denote unavailable inputs, not observed neutral readings.

Low-conviction monitoring view. The packet's positive deterministic prior reflects earlier evidence, but the purported October 15 earnings event could not be confirmed. The $22.80 October 19 anchor does not establish an earnings-driven market reaction. Post-print analyst revisions and consensus comparisons are unavailable; zero sentiment fields denote unavailable measurements, not neutral observations. Avoid confusing UNB with Atlantic Union Bankshares (AUB).

The deterministic prior turned positive on a scheduled earnings trigger, but the October 16 date is described by earnings calendars as estimated and unconfirmed; the latest company results confirmed in this evidence remain Q2. Thus there is no defensible Q3 beat/miss, post-print revision or earnings-linked price reaction to report. The October 16 anchor is a price reference, not evidence of an earnings reaction. The stored September earnings-context article is third-party commentary, not a company release. [Earnings-date status](https://www.marketbeat.com/stocks/NASDAQ/RBCAA/earnings/) [SEC filing history](https://www.sec.gov/edgar/browse/index.html?cik=921557)

The filing-supported Q3 beat strengthens the April baseline, consistent with the deterministic positive prior and high evidence-quality score. Initial reaction was mixed: [Investing.com reported an approximately 4.4% premarket decline](https://www.investing.com/news/earnings/travelers-beats-estimates-but-shares-slip-on-catastrophe-losses-4953755), while the packet's October 16 adjusted-close anchor is $389.54; available price feeds do not support a precise, uncontested close-to-close reaction. Verified post-print analyst revisions remain limited, and missing revisions are not positive evidence. Social, options, short-interest and employee metrics were not supplied; their zero values above indicate unavailable data, not measured neutral readings.

The initial reaction was mixed: [MT Newswires](https://finance.yahoo.com/markets/stocks/articles/truist-financial-q3-adjusted-earnings-111137654.html) reported a premarket decline, but TFC closed October 16 at $47.07, up 1.07% on the day ([price history](https://www.financecharts.com/stocks/TFC/summary/price)). The scheduled T+1 follow-up adds substantive Q3 results and outlook to the earlier monitoring thesis, while the identified Keefe Bruyette estimate and target cuts temper the deterministic positive prior. Broader post-print revisions and sustained price reaction remain unverified; no usable social, options or employee-sentiment measures were supplied.

Midday Need to Know : Warsh sticks to messaging strategy , AI data center spending surges , and more ( SP500 :)